Summit Therapeutics (SMMT) EBT Margin (2017 - 2022)
Summit Therapeutics (SMMT) posted quarterly EBT Margin of 8014.55% for Q3 2022, down 651730.0% year-on-year from N/an in Q3 2021, and down 41.13% on a QoQ basis from 5678.72% in Q2 2022.
Summit Therapeutics (SMMT) EBT Margin (2017 - 2022) Analysis & Trends
Summit Therapeutics (SMMT) has reported EBT Margin for 6 consecutive years, with 8014.55% the latest figure, recorded in Q3 2022.
- Quarterly EBT Margin fell 651730.0% year-over-year to 8014.55% in Q3 2022, while the trailing twelve-month figure through Jun 2023 was 273511.82% (down 26947769.0% YoY) and the FY2022 annual result came in at 11174.75%, down 627691.0% from the prior year.
- EBT Margin eased to 8014.55% in Q3 2022 per SMMT's latest filing, from 5678.72% in the prior quarter.
- Over the last five years, EBT Margin for SMMT reached as high as 91.21% in Q4 2019 and fell as low as 42835.09% in Q2 2021.
- A 5-year average of 6718.02% and a median of 5308.01% in 2019 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2021 — EBT Margin sank 3373509 bps — and 2022, when it surged 3715636 bps.
- Year by year, EBT Margin stood at 1393.93% in 2018, then surged by 107 bps to 91.21% in 2019, then tumbled by 8137 bps to 7330.81% in 2020, then tumbled by 47 bps to 10796.41% in 2021, then advanced by 26 bps to 8014.55% in 2022.
- According to Business Quant data, EBT Margin over the past three periods registered 8014.55%, 5678.72%, and 8982.0% for Q3 2022, Q2 2022, and Q1 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Summit Therapeutics | 11.62 Bn | 11.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -8,014.55% |
| Jun 30, 2022 | -5,678.72% |
| Mar 31, 2022 | -8,982.00% |
| Dec 31, 2021 | -10,796.41% |
| Sep 30, 2021 | -1,497.25% |
| Jun 30, 2021 | -42,835.09% |
| Mar 31, 2021 | -9,108.33% |
| Dec 31, 2020 | -7,330.81% |
| Sep 30, 2020 | -9,833.70% |
| Jun 30, 2020 | -9,100.00% |
| Mar 31, 2020 | -2,365.52% |
| Dec 31, 2019 | 91.21% |
| Oct 31, 2019 | -6,255.65% |
| Sep 30, 2019 | -4,233.11% |
| Jul 31, 2019 | -4,937.30% |
| Mar 31, 2019 | -1,645.07% |
| Oct 31, 2018 | -1,393.93% |
| Jul 31, 2018 | 71.46% |
| Apr 30, 2018 | -175.22% |
| Jan 31, 2018 | -340.33% |